DBV Technologies (DBVT) EBT Margin (2020 - 2026)
DBV Technologies (DBVT) posted quarterly EBT Margin of 7171.43% for Q2 2026, down 438476.0% year-on-year from N/an in Q2 2025, and down 36.17% on a QoQ basis from 5266.67% in Q1 2026.
DBV Technologies (DBVT) EBT Margin (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported EBT Margin for 7 consecutive years, with 7171.43% the latest figure, recorded in Q2 2026.
- Quarterly EBT Margin fell 438476.0% year-over-year to 7171.43% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3491.11% (down 37947.0% YoY) and the FY2025 annual result came in at 2598.58%, up 11244.0% from the prior year.
- EBT Margin retreated to 7171.43% in Q2 2026 per DBVT's latest filing, from 5266.67% in the prior quarter.
- Over the last five years, EBT Margin for DBVT reached as high as 3010.58% in Q4 2022 and fell as low as 7171.43% in Q2 2026.
- A 5-year average of 2291.73% and a median of 1723.44% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 347610 bps — and 2026, when it sank 438476 bps.
- Year by year, EBT Margin stood at 3010.58% in 2022, then tumbled by 104 bps to 126.11% in 2023, then plunged by 3158 bps to 4108.57% in 2024, then sank by 68 bps to 6892.25% in 2025, then slipped by 4 bps to 7171.43% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 7171.43%, 5266.67%, and 6892.25% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -7,171.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,171.43% |
| Mar 31, 2026 | -5,266.67% |
| Dec 31, 2025 | -6,892.25% |
| Sep 30, 2025 | -1,195.53% |
| Jun 30, 2025 | -2,786.67% |
| Mar 31, 2025 | -3,387.50% |
| Dec 31, 2024 | -4,108.57% |
| Sep 30, 2024 | -2,839.74% |
| Jun 30, 2024 | -2,852.37% |
| Mar 31, 2024 | -1,940.09% |
| Dec 31, 2023 | -126.11% |
| Sep 30, 2023 | -705.56% |
| Jun 30, 2023 | -1,059.00% |
| Mar 31, 2023 | -937.15% |
| Dec 31, 2022 | 3,010.58% |
| Sep 30, 2022 | -833.51% |
| Jun 30, 2022 | -1,506.80% |
| Mar 31, 2022 | -652.75% |
| Dec 31, 2021 | -465.52% |
| Sep 30, 2021 | -1,816.55% |